{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:37:39Z","timestamp":1793666259045,"version":"4.5.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":448,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jtct.2021.11.009","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T21:03:30Z","timestamp":1637787810000},"page":"158.e1-158.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4983-5039","authenticated-orcid":false,"given":"Anand","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3625-2416","authenticated-orcid":false,"given":"Enass","family":"Raffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna A.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogi","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yueh","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-1977","authenticated-orcid":false,"given":"Joerg","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.11.009_bib0001","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.bbmt.2009.07.007","article-title":"Impact of declining fertility rates in Canada on donor options in blood and marrow transplantation","volume":"15","author":"Allan","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0002","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.11.009_bib0003","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/asheducation.V2012.1.230.3798312","article-title":"Haploidentical transplantation for hematologic malignancies: where do we stand?","volume":"2012","author":"Fuchs","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2021.11.009_bib0004","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM198509263131301","article-title":"Marrow transplantation from related donors other than HLA-identical siblings","volume":"313","author":"Beatty","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.11.009_bib0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0198-8859(90)90071-V","article-title":"Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma","volume":"29","author":"Anasetti","year":"1990","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0006","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0007","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0008","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/bmt.2009.311","article-title":"The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched\/haploidentical transplantation: a comparative analysis","volume":"45","author":"Xu","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0009","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0010","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.bbmt.2020.07.021","volume":"26","author":"Algwaiz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9736564","article-title":"Myeloablative conditioning with PBSC grafts for T cell-replete haploidentical donor transplantation using posttransplant cyclophosphamide","volume":"2016","author":"Solomon","year":"2016","journal-title":"Adv Hematol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0012","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0013","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbmt.2016.02.001","article-title":"Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders","volume":"22","author":"Klein","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0014","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/leu.2016.125","article-title":"Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European Society for Blood and Marrow Transplantation","volume":"30","author":"Dietrich","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.11.009_bib0015","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0016","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0017","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.11.009_bib0018","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.bbmt.2020.04.001","article-title":"Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"26","author":"Hamadani","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0019","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41409-020-0873-x","article-title":"The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage","volume":"55","author":"Szer","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-020-01063-2","article-title":"Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia","volume":"56","author":"Saglio","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.02.010","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source","volume":"27","author":"Trujillo","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2021.11.009_bib0022","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.bbmt.2018.06.034","article-title":"Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients","volume":"24","author":"Hong","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000002030","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide for pediatric acute leukemia is safe and effective","volume":"43","author":"Sharma","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.25661","article-title":"Haploidentical transplantation in high-risk pediatric leukemia: a retrospective comparative analysis on behalf of the Spanish working group for bone marrow transplantation in children (GETMON) and the Spanish grupo for hematopoietic transplantation (GETH)","volume":"95","author":"P\u00e9rez-Mart\u00ednez","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0025","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.bbmt.2018.12.168","volume":"25","author":"Symons","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0026","first-page":"573","article-title":"Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia","volume":"55","author":"Storb","year":"1983","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0027","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood.V59.2.236.236","article-title":"Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients","volume":"59","author":"Storb","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0028","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.11.009_bib0029","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0030","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0031","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0032","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0033","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0034","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.11.009_bib0035","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.20.00494","article-title":"Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from Children's Oncology Group AALL0932","volume":"39","author":"Angiolillo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0036","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0037","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1002\/cam4.3290","article-title":"Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: a single-center retrospective study","volume":"9","author":"Huang","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2021.11.009_bib0038","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41375-019-0544-3","article-title":"Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT","volume":"34","author":"Shem-Tov","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.11.009_bib0039","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT","volume":"104","author":"Brissot","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.11.009_bib0040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.11.009_bib0041","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0042","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbmt.2018.02.002","article-title":"HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison","volume":"24","author":"Devillier","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0043","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.25231","article-title":"Comparable outcomes of haploidentical, 10\/10 and 9\/10 unrelated donor transplantation in adverse karyotype AML in first complete remission","volume":"93","author":"Lorentino","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0044","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0045","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.11.009_bib0046","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","article-title":"Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study","volume":"34","author":"Yu","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.11.009_bib0047","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA haploidentical versus matched unrelated donor transplants with post-transplant cyclophosphamide based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0048","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-019-0459-7","article-title":"Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed\/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT","volume":"54","author":"Battipaglia","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0049","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"Salvatore","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.11.009_bib0050","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0051","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-021-01065-7","volume":"14","author":"Nagler","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0052","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.11.009_bib0053","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.11.009_bib0054","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s10875-020-00898-0","article-title":"Reduced intensity bone marrow transplantation with post-transplant cyclophosphamide for pediatric inherited immune deficiencies and bone marrow failure syndromes","volume":"41","author":"Klein","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0055","series-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","first-page":"539","article-title":"Acute lymphoblastic leukemia in children and adolescents","author":"Peters","year":"2019"},{"key":"10.1016\/j.jtct.2021.11.009_bib0056","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbmt.2016.11.016","article-title":"Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies","volume":"23","author":"Klein","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0057","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell\u2013replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0058","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cncr.31228","article-title":"Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2021.11.009_bib0059","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/16078454.2020.1831292","article-title":"Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis","volume":"25","author":"Ma","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.jtct.2021.11.009_bib0060","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood-2010-01-261958","article-title":"Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors","volume":"116","author":"Shaw","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.009_bib0061","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.bbmt.2018.08.010","article-title":"Bone marrow versus peripheral blood from unrelated donors for children and adolescents with acute leukemia","volume":"24","author":"Keesler","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0062","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbmt.2019.07.025","article-title":"Allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation for hematologic malignancies in children: a systematic review and meta-analysis","volume":"26","author":"Shimosato","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0063","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.bbmt.2016.06.019","article-title":"Haploidentical versus matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia: should donor type matter anymore?","volume":"22","author":"Solomon","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.009_bib0064","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0171-2985(96)80033-7","article-title":"Cyclophosphamide-induced immunological tolerance: an overview","volume":"195","author":"Mayumi","year":"1996","journal-title":"Immunobiology"},{"key":"10.1016\/j.jtct.2021.11.009_bib0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtct.2021.11.009_bib0066","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41409-018-0133-5","article-title":"Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years","volume":"53","author":"Debals-Gonthier","year":"2018","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721013956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721013956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:03:29Z","timestamp":1763003009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721013956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2666636721013956"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.11.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}